Cynosure, Inc. (NASDAQ:CYNO) – Research analysts at Northcoast Research increased their Q2 2017 EPS estimates for Cynosure in a research note issued to investors on Tuesday. Northcoast Research analyst E. Snyder now forecasts that the brokerage will earn $0.44 per share for the quarter, up from their previous estimate of $0.42. Northcoast Research currently has a “Neutral” rating on the stock. Northcoast Research also issued estimates for Cynosure’s Q3 2017 earnings at $0.39 EPS and Q4 2017 earnings at $0.51 EPS.

Cynosure (NASDAQ:CYNO) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.03. Cynosure had a return on equity of 6.86% and a net margin of 3.56%. The company earned $122.10 million during the quarter, compared to the consensus estimate of $119.97 million. During the same period last year, the company earned $0.42 earnings per share. The firm’s revenue was up 19.2% compared to the same quarter last year.

This piece of content was reported by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be accessed at http://www.watchlistnews.com/northcoast-research-brokers-raise-earnings-estimates-for-cynosure-inc-cyno/1120630.html.

Earnings History and Estimates for Cynosure (NASDAQ:CYNO)

Several other research firms also recently weighed in on CYNO. TheStreet upgraded Cynosure from a “hold” rating to a “buy” rating in a research note on Wednesday, January 4th. Northland Securities restated an “outperform” rating and issued a $60.00 price target on shares of Cynosure in a research note on Thursday. Maxim Group downgraded Cynosure from a “buy” rating to a “hold” rating and set a $66.00 price target on the stock. in a research note on Tuesday. Zacks Investment Research downgraded Cynosure from a “hold” rating to a “sell” rating in a research note on Wednesday, October 26th. Finally, Aegis restated a “buy” rating and issued a $60.00 price target on shares of Cynosure in a research note on Tuesday, January 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $57.88.

Shares of Cynosure (NASDAQ:CYNO) remained flat at $66.00 during trading on Thursday. The stock had a trading volume of 884,228 shares. Cynosure has a 1-year low of $37.32 and a 1-year high of $66.50. The company has a 50 day moving average price of $48.91 and a 200-day moving average price of $48.55. The firm has a market capitalization of $1.56 billion, a P/E ratio of 101.54 and a beta of 1.65.

In other Cynosure news, Chairman Michael R. Davin sold 16,284 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total transaction of $732,780.00. Following the sale, the chairman now directly owns 4,222 shares in the company, valued at approximately $189,990. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Douglas J. Delaney sold 7,875 shares of the stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $354,375.00. Following the sale, the vice president now owns 5,833 shares in the company, valued at $262,485. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

This piece of content was reported by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be accessed at http://www.watchlistnews.com/northcoast-research-brokers-raise-earnings-estimates-for-cynosure-inc-cyno/1120630.html.

A number of hedge funds have recently modified their holdings of the stock. Albion Financial Group UT increased its stake in shares of Cynosure by 9.1% in the third quarter. Albion Financial Group UT now owns 215,079 shares of the company’s stock valued at $10,956,000 after buying an additional 17,917 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Cynosure by 2.4% in the third quarter. Bank of New York Mellon Corp now owns 427,418 shares of the company’s stock valued at $21,773,000 after buying an additional 10,192 shares in the last quarter. Rothschild Asset Management Inc. increased its stake in shares of Cynosure by 6.2% in the third quarter. Rothschild Asset Management Inc. now owns 424,820 shares of the company’s stock valued at $21,640,000 after buying an additional 24,874 shares in the last quarter. Hood River Capital Management LLC increased its stake in shares of Cynosure by 14.8% in the third quarter. Hood River Capital Management LLC now owns 205,686 shares of the company’s stock valued at $10,478,000 after buying an additional 26,497 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Cynosure by 7.1% in the third quarter. BlackRock Fund Advisors now owns 1,722,652 shares of the company’s stock valued at $87,752,000 after buying an additional 114,653 shares in the last quarter.

About Cynosure

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

5 Day Chart for NASDAQ:CYNO

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.